Adaptin Bio, Inc. (APTN)

AI-Powered SEC Filing Analysis

Current Report Filed: 2026-04-06

Key Insights

  • Adaptin Bio, Inc. has announced that its common shares have been approved for quotation on the OTCQB® Venture Market, which provides investors with increased visibility and access to the company's stock.
  • As an emerging growth company, Adaptin Bio has elected not to use the extended transition period for complying with new or revised financial accounting standards, indicating a commitment to transparency and timely reporting.
  • The company's headquarters are located in Charlotte, North Carolina, suggesting a potential focus on the southeastern U.S. market and regional business development opportunities.
Filing tone (AI): Positive
View Original Filing →
Annual Report Filed: 2026-04-01

Key Insights

  • The company has been active in subsequent events, including two private placements in February and March 2026 involving the issuance of common stock and warrants.
  • The company granted stock options and performance shares to directors, officers, and consultants during the fiscal year 2025.
  • The company had several debt instruments outstanding, including secured promissory notes, private exchange notes, and convertible debt, which were converted or exchanged during the fiscal year 2025.
Filing tone (AI): Neutral
View Original Filing →

Filings on this page are at least 90 days old. In the app, any new Adaptin Bio, Inc. filing is analysed the moment you open it.

Download on theApp Store Get it onGoogle Play

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.